Annex 1 to EU GMP: The Unfinished Business of Implementation in the Pharmaceutical Industry

However, two years on, industry surveys and regulatory inspection feedback reveal that implementation is far from complete. While many companies have made progress on documentation and procedural updates, practical integration into operations—especially in legacy facilities—continues to pose challenges. Among the most contentious areas is Pre-Use Post-Sterilization Integrity Testing (PUPSIT), a topic that has drawn particular scrutiny.

1. PUPSIT: The Persistent Dilemma

What is PUPSIT?

PUPSIT requires that sterilizing-grade filters be integrity tested after sterilization and before use, to ensure they function correctly and have not been damaged during sterilization. This is to prevent the undetected use of compromised filters during aseptic manufacturing.

Why It’s Challenging:

• Technical Limitations: For some legacy equipment and product types (e.g., viscous solutions, small volume parenterals), performing a reliable PUPSIT is mechanically or physically impractical.
• Risk of False Failures or Contamination: Conducting PUPSIT may require breaking sterility barriers or manipulating connections, introducing new risks.
• Regulatory Ambiguity: While Annex 1 sets PUPSIT as a default requirement, it allows for exceptions only with strong justification based on risk assessment and historical data. Regulators have shown variable tolerance for such justifications.
• Cost and Complexity: Retrofitting equipment to enable automated, in-line PUPSIT (especially for isolators and closed systems) can be prohibitively expensive for older facilities.

The Regulatory Expectation:

Unless a robust case is made, companies are expected to perform PUPSIT as standard, with detailed documentation of the method, outcomes, and rationale for any deviations. As such, many manufacturers are under pressure to upgrade or revalidate systems they had not previously considered deficient.

1. Contamination Control Strategy (CCS): Complex and Cross-Functional

A foundational expectation of Annex 1 is the development and active use of a Contamination Control Strategy that ties together facility design, equipment, personnel, and monitoring. Many firms are still struggling to implement a comprehensive CCS that reflects true operational practice and is consistently updated.

Challenges include:

• Aligning existing controls with new expectations retrospectively
• Documenting informal practices or undocumented rationales
• Integrating data across departments (e.g., QC, QA, Engineering)
• Not considering the CCS as a living document

1. Environmental Monitoring (EM): Expanded Expectations

Annex 1 has raised the bar for:

• Sampling locations and frequencies
• Trending and response requirements
• Rapid microbial method integration

Legacy facilities may lack infrastructure and digital tools for real-time data analysis. Operators often lack training to interpret trend data effectively.

1. Aseptic Process Simulation (APS) Realism

Media fills now need to reflect worst-case scenarios and human interventions—many of which were not historically considered part of routine validation. This has led to:

• Redesign of simulation protocols
• Increased resource demand for testing and review
• Delays in requalifying legacy lines, especially with RABs or isolators

1. Facility and HVAC Constraints

Cleanroom classification, airflow visualization, and differential pressures are under new scrutiny. Particularly:

• Older HVAC systems may not meet revised Annex 1 tolerances
• Pressure mapping often reveals non-compliance during requalification
• Preexisting SOPs and design documentation are often misaligned with actual conditions

1. Data Integrity and Hybrid Systems

Despite guidance in Annex 11, many manufacturers still operate with hybrid systems (paper + electronic), increasing the risk of:

• Audit trail gaps
• Duplicate records
• Incomplete version control of procedures and batch records

Annex 1’s emphasis on process transparency and traceability requires digital maturity that many systems lack.

1. Personnel Practices and Aseptic Behaviour

Enhanced requirements for gowning, training, and behaviour in Grade A/B areas expose gaps in:

• Ongoing operator qualification and requalification
• Observation and feedback mechanisms
• Visual inspection competence and documentation

1. Organizational and Cultural Hurdles

True implementation depends not just on new SOPs, but on cross-functional ownership and accountability. Barriers include:

• Resistance to change in legacy organizations
• Delayed investment in modernization
• Misalignment between Quality, Operations, and Engineering

Conclusion: The Gap Between Theory and Practice

The revised Annex 1 represents a shift from procedural compliance to risk-based sterility assurance and operational maturity. While it offers a clear vision for modern pharmaceutical manufacturing, many companies remain at the halfway point—acknowledging the requirements but struggling to execute them, especially in areas like PUPSIT and CCS.

For the industry, the path forward lies in:

• Embracing technology and automation where feasible
• Investing in training and culture change
• Collaborating with regulators on justified alternatives when needed

Annex 1 is not just a checklist—it’s a challenge to rethink how sterile medicines are made and assured. Meeting that challenge requires both strategic investment and operational courage.